Larimar Therapeutics (LRMR) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 58.3% versus a loss of 52.7%. Over five years, SLGL leads with a -29.1% price change compared with -84.5% for LRMR. Sol-Gel Technologies is the larger company by market cap ($210.4 million vs $206.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | SLGL |
|---|---|---|
| Share price | $1.99 | $64.25 |
| Market cap | $206.21M | $210.35M |
| 1-day change | -0.25% | -6.48% |
| YTD return | -47.90% | +52.47% |
| 1-year return | -52.74% | +58.25% |
| 5-year return | -84.48% | -29.10% |
| EPS (TTM) | $-1.99 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $19.39M |
| Revenue growth (YoY) | — | +68.04% |
| Net income (latest FY) | $-165.67M | $-6.13M |
| Operating margin | — | -38.88% |
| Net margin | — | -31.60% |
| 52-week high | $6.42 | $97.97 |
| 52-week low | $1.92 | $28.81 |
| Distance from 52-week high | -69.08% | -34.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +625.44% | +137.35% |
| Average volume | 1.31M | 54.96K |
| Shares outstanding | 103.88M | 3.27M |
| Employees | 71 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed LRMR by 111.0 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
LRMR vs SLGL FAQ
Which is bigger, Larimar Therapeutics or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $210.35M compared with $206.21M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, LRMR or SLGL?
SLGL returned +58.25% over the past 12 months, compared with -52.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.